Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug that raises high-density lipoprotein cholesterol and has a lower discontinuation rate than that of Abbott's Niaspan ER (extended release) would earn a 20 percent patient share in the treatment of dyslipidemia, according to surveyed endocrinologists.

The new report entitled Dyslipidemia: Blockbuster Potential for Agents that Target HDL finds that although lowering low-density lipoprotein cholesterol levels is at the forefront of treating dyslipidemia, researchers are now aware that increasing high-density lipoprotein cholesterol levels may also help reduce cardiovascular risk.

The report also finds that surveyed endocrinologists do not expect any therapy under development to displace AstraZeneca's Crestor as the Decision Resources' proprietary clinical gold standard for dyslipidemia through 2016. Although some therapies in development hold promise, most have efficacy, safety and tolerability, and/or delivery features that merit inferior scores compared with Crestor.

"For the majority of end points, endocrinologists we surveyed perceive the statin class to be very similar," said Graeme Green, Ph.D., analyst at Decision Resources. "However Crestor positively differentiates itself in its greater ability to improve low- and high-density lipoprotein cholesterol levels."

About the Report

Dyslipidemia: Blockbuster Potential for Agents that Target HDL is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Elizabeth Marshall   Decision Resources   781-296-2563   emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Elizabeth Marshall of Decision Resources, +1-781-296-2563,
emarshall@dresources.com

Lori Silver Joins Decision Resources, Inc. as General Counsel

View Now